News | December 01, 2023
Biocon Biologics completes Integration of Viatris' Biosimilar business
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
The company also organised sensitization workshops for its employees aimed at increasing awareness of challenges faced by hearing-impaired individuals
South Asia’s largest Trade Fair for pharma brought together over 50,000 visitors from across the globe, more than 1,500 exhibitors showcasing 10,000+ products and representation from over 80 countries
Equipped with most advanced Distributed Control System (DCS) automation technology, the facility has been set up with an investment of Rs. 200 crore
Establishes connected software and data foundation for the future with next-generation life sciences CRM and harmonized customer data
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Both the India and GCC entities will be operated by separate dedicated management teams
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
Subscribe To Our Newsletter & Stay Updated
